Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | BRAF | P15056 | 2/20 | 0.54 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | PIR | O00625 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.54 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | STK16 | O75716 | 1/20 | 0.54 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | FES | P07332 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298244 | 0.92 | CYP3A4 (0.84) | CYP3A4CYP2C9CYP2C19CYP2D6BRAF | |
| SCHEMBL2162818 | 0.92 | CYP3A4 (0.73) | CYP3A4CYP2C9CYP2C19CYP2D6BRAF | |
| SCHEMBL297958 | 0.91 | CYP3A4 (0.79) | CYP3A4CYP2C9CYP2C19CYP2D6BRAF | |
| SCHEMBL2164955 | 0.90 | CYP3A4 (0.75) | CYP3A4CYP2C9CYP2C19CYP2D6BRAF | |
| SCHEMBL299579 | 0.89 | CYP3A4 (0.72) | CYP3A4CYP2C9CYP2C19CYP2D6BRAF | |
| SCHEMBL292446 | 0.89 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6BRAF | |
| SCHEMBL298913 | 0.89 | CYP3A4 (0.76) | CYP3A4CYP2C9CYP2C19CYP2D6BRAF | |
| SCHEMBL291570 | 0.89 | CYP2C9 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6BRAF | |
| SCHEMBL410805 | 0.89 | CYP3A4 (0.84) | CYP3A4CYP2C9CYP2C19CYP2D6BRAF | |
| SCHEMBL298954 | 0.88 | CYP3A4 (0.80) | CYP3A4CYP2C9CYP2C19CYP2D6BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406259-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2012-01-18 | — | — | EP | claimed |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2010-11-11 | — | — | US | claimed |
| WO-2010104945-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2406259-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-2406259-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2010-11-11 | — | — | US | disclosed |
| WO-2010104945-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010104945-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CYP3A4 1288/4885CYP2C9 871/4885CYP2C19 1536/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CYP3A4 1288/4885CYP2C9 871/4885CYP2C19 1536/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CYP3A4 1288/4885CYP2C9 871/4885CYP2C19 1536/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | CYP3A4 3203/4885CYP2C9 4092/4885CYP2C19 4082/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | CYP3A4 4591/4885CYP2C9 4816/4885CYP2C19 4731/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CYP3A4 1288/4885CYP2C9 871/4885CYP2C19 1536/4885 |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DDOST, DAD1, PHGDH | CYP3A4 3525/4885CYP2C9 4097/4885CYP2C19 3893/4885 |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | BRAF, RAF1, FER | CYP3A4 3815/4885CYP2C9 2194/4885CYP2C19 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.